{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464382597
| IUPAC_name = 4-<nowiki/>{(''S'')-hydroxy[(2''R'')-piperidin-2-yl]methyl}benzene-1,2-diol
| image = Rimiterol.svg
| width = 200
| image2 = Rimiterol ball-and-stick model.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 32953-89-2
| ATC_prefix = R03
| ATC_suffix = AC05
| ATC_supplemental =  
| PubChem = 36283
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1097630
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 33366
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 26GIW6ZLPH

<!--Chemical data-->
| C=12 | H=17 | N=1 | O=3 
| molecular_weight = 223.268 g/mol
| smiles = O[C@@H](c1ccc(O)c(O)c1)[C@@H]2NCCCC2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H17NO3/c14-10-5-4-8(7-11(10)15)12(16)9-3-1-2-6-13-9/h4-5,7,9,12-16H,1-3,6H2/t9-,12+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IYMMESGOJVNCKV-SKDRFNHKSA-N
}}

'''Rimiterol''' ([[International Nonproprietary Name|INN]]/[[United States Adopted Name|USAN]]) is a third-generation<ref>{{Cite journal | last1 = Palma-Carlos | first1 = A. G. | last2 = Palma-Carlos | first2 = G. S. | title = Beta-2-agonists of Third Generation | journal = Allergie et Immunologie | volume = 18 | issue = 4 | pages = 31–32, 35 | year = 1986 | pmid = 2899434}}</ref> short-acting<ref>{{cite journal|last1=Lai|first1=CK|last2=Twentyman|first2=OP|last3=Holgate|first3=ST|title=The Effect of an Increase in Inhaled Allergen Dose After Rimiterol Hydrobromide on the Occurrence and Magnitude of the Late Asthmatic Response and the Associated Change in Nonspecific Bronchial Responsiveness|journal=The American Review of Respiratory Disease|date=October 1989|volume=140|issue=4|pages=917–23|pmid=2572192|doi=10.1164/ajrccm/140.4.917}}</ref><ref>{{cite journal|last1=Ydreborg|first1=SO|last2=Svedmyr|first2=N|last3=Thiringer|first3=G|title=Comparison of Rimiterol and Terbutaline, Given by Aerosol, in a Long-term Study|journal=Scandinavian Journal of Respiratory Diseases|date=April 1977|volume=58|issue=2|pages=117–24|pmid=16339}}</ref> [[Beta2-adrenergic agonist|β<sub>2</sub> agonist]].

==See also==
*[[Isoprenaline]]
*[[Colterol]]

==References==
{{reflist}}

{{Asthma and copd rx}}
{{Adrenergic agonists}}

[[Category:Beta-adrenergic agonists]]
[[Category:Catecholamines]]
[[Category:Piperidines]]

{{respiratory-system-drug-stub}}